



Chemotherapy-Induced Nausea and Vomiting



Introduction •

Product Information

ANZEMET® Formulary Kit

Patient Assistance and Reimbursement Programs

Managed Care

Professional Support

[Sign Up for More Information](#)

[Anzemet.com Home](#)

For help and inspiration in dealing with nausea and vomiting, tell your patients to...

Go to



Proven 24-hour control with just one dose

A single-dose regimen at the lowest fully effective dose can provide economic benefit and the potential for reduced side effects.

Gralla RJ, et al. ASCO Recs for the use of antiemetics in clinical practice guideline 1999;17(9):2971-2994.

The management of chemotherapy-induced nausea and vomiting is a critical aspect of cancer patient care. Antiemetic therapy has become increasingly important to manage the side effects associated with more-aggressive chemotherapy regimens.⁵


The advent of 5-HT₃ receptor antagonists was a significant breakthrough for the practice of oncology. These agents offer greater efficacy and safety than traditional antiemetic therapies, such as metoclopramide.^{4,6} Greater control over the vomiting that immediately follows chemotherapy may also help prevent anticipatory nausea and vomiting in subsequent courses of chemotherapy—interrupting a pernicious cycle.^{5,7}

Special features:

- ANZEMET® CARE Calc
- Emetogenic Potential
- Patient comfort items
- eGreeting tool
- Patient education materials
- Resources for patient assistance
- CARE Rebate

IV Optimal control with a single dose

24-HOUR EMESIS PREVENTION WITH VARYING DOSES OF CISPLATIN*



A single dose of ANZEMET® prevents nausea and vomiting in the majority of patients receiving high-dose cisplatin.^{1,2,3,4}

*Results from two separate, multi-center, double-blind, randomized studies. ANZEMET® dose was 1.8 mg/kg. Complete response defined as no emetic episodes and no rescue medication for 24 hours after dosing.

Zofran® is a registered trademark of Glaxo Group Limited.

Kytril® is a registered trademark of Hoffman-La Roche Inc.

ANZEMET® (dolasetron mesylate) is a specific and selective 5-HT₃ receptor antagonist available for single-dose intravenous and oral prevention of CINV. The recommended oral doses of ANZEMET® have been characterized in extensive clinical trials. For complete dosing information, healthcare providers can prescribe with maximum confidence.

ANZEMET® Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including high-dose cisplatin.

The most common adverse events (>4%) in chemotherapy patients are headache, fatigue, diarrhea, and bradycardia.

headache, diarrhea, and fever (injection).

ANZEMET® can cause ECG interval changes; it should be administered with caution in patients who have or may de
prolongation of cardiac conduction intervals.

Please see full prescribing information for ANZEMET® Injection and ANZEMET® Tablets.

© 2003 Aventis Pharmaceuticals Inc. This site is intended for use by U.S. residents only.
[Aventis Pharmaceuticals U.S. Home Page](#) [Terms of Use](#) [Privacy Policy](#)

ANZ-WS-8581-1